Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2022 Earnings Conference Call March 15, 2022 4:30 PM ET Company Participants Ronnie Morris – Chief Executive Officer David Miller – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Capital Group Operator Good afternoon, ladies and gentlemen, and welcome to the Champions Oncology Third Quarter Fiscal Year 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode. And we will open the floor for your questi ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|----------------- ...

Revenue Performance - Oncology services revenue for the three months ended October 31, 2021, was $11.8 million, a 16.5% increase from $10.1 million in the same period of 2020[111] - For the six months ended October 31, 2021, oncology services revenue reached $23.0 million, up 17.2% from $19.7 million in the prior year[111] Gross Margins - Gross margins for oncology services improved to 52.4% for the three months ended October 31, 2021, compared to 44.2% in the same period of 2020[112] Expenses - Research and development expenses increased by 39.3% to $2.3 million for the three months ended October 31, 2021, from $1.7 million in 2020[113] - Sales and marketing expenses rose by 21.7% to $1.6 million for the three months ended October 31, 2021, compared to $1.3 million in the same period of 2020[114] - General and administrative expenses increased by 34.5% to $2.0 million for the three months ended October 31, 2021, from $1.5 million in 2020[115] - Total costs and operating expenses for the six months ended October 31, 2021, were $22.9 million, a 16.9% increase from $19.6 million in 2020[110] Cash Flow and Financial Position - Net cash provided by operating activities was $1.4 million for the six months ended October 31, 2021, compared to $164,000 in the same period of 2020[118] - The company had an accumulated deficit of approximately $72.4 million as of October 31, 2021[107] - Cash on hand as of October 31, 2021, was $4.8 million, with working capital of $1.2 million[107]

Financial Data and Key Metrics Changes - The first quarter revenue reached a record $11.3 million, an increase of $1.7 million or 18% compared to $9.5 million in the same period last year [11] - Gross margin improved to 53% from 44% year-over-year, despite total cost of sales remaining flat at $5.3 million [12][13] - Cash-based expenses increased to $10.8 million from $9.1 million, primarily due to increased R&D investment and salesforce expansion [16] Business Line Data and Key Metrics Changes - The oncology research services business continued to expand and produce positive financial results, contributing to overall revenue growth [10] - R&D expenses rose to approximately $2.3 million, a 44% increase from $1.6 million, reflecting a strategic focus on long-term growth [14] - Sales and marketing expenses increased by 31% to $1.5 million, driven by compensation-related expenses from an expanded sales team [15] Market Data and Key Metrics Changes - The company has sold licenses to over 100 unique customers for its new software platform Lumin, indicating strong market interest [7] - The European lab is operational, with expectations to begin signing contracts by the end of the year, enhancing the company's international capabilities [25][28] Company Strategy and Development Direction - The company is focused on leveraging its unique PDX tumor bank and scientific platform to enhance its oncology research services and software offerings [6] - A new software platform, Lumin, has been launched, aimed at providing advanced data interpretation capabilities, with ongoing development based on customer feedback [7] - The company is advancing therapeutic targets through its internal computational discovery team, validating more than six targets for further development [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robustness of budgets and pipelines, particularly in the preclinical space, despite some delays in decision-making due to the pandemic [32] - The company anticipates continued growth in its biomarker business, particularly with the opening of the European lab, which is expected to facilitate larger studies [27][28] - Management is optimistic about the future, highlighting the strength of the oncology services business and the potential of the software services and therapeutic discovery initiatives [35] Other Important Information - The company reported no debt and had $4 million in cash at the end of the first fiscal quarter [17] - Net cash generated from operating activities was $216,000, while cash used in investing activities was primarily for software platform development and laboratory expansions [17] Q&A Session Summary Question: Feedback on customer renewals and expansions - Management noted that renewal rates were over 80% for a small number of contracts, emphasizing the importance of user comfort with the platform [22] Question: Update on the services component of the Lumin platform - The services component has launched and is seeing traction, expected to be a significant revenue driver as customers engage more deeply with the platform [24] Question: Status of the European lab and contract signing - The European lab is operational, with compliance certification in progress, and management expects to begin serious proposals by the end of the year [25] Question: Progress of the flow cytometry business - The biomarker business is growing steadily, with the European site expected to enhance capabilities for larger studies [27][28] Question: Impact of pandemic on business operations - The company has not seen significant fluctuations in preclinical business, with robust budgets and strong customer return rates [32]

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|-------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |------------------------------------------------------------------------------------------ ...

Creating Greater Certainty in the Fight Against Cancer ACCELERATING DRUG DISCOVERY Investor Relations Presentation March 2021 Notice of Forward-Looking Statements This presentation contains certain "forward-looking statements," which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding projections, predictions ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|----------------- ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. | --- | --- | |----------------------------------------------------------------------------|----------------- ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2021 Earnings Conference Call September 14, 2020 4:30 PM ET Company Participants Ronnie Morris - President and CEO David Miller - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Scott Henry - ROTH Capital Operator Greetings and welcome to Champions Oncology First Quarter Fiscal Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator ...